GlassScriptPhysician profile
Brooks S Lide
NPI 1083777056
$1,366.17
in general payments reported to CMS, 2019-2025
26 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $68.15 · 2021: $308 · 2022: $140 · 2023: $298 · 2024: $95.16 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $237.22 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $212.75 | 2019-2025 | |
| Lilly USA, LLC | $121.93 | 2021-2025 | Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $101.22 | 2020-2021 | |
| Radius Health, INC. | $66.13 | 2025 | Tymlos |
| Astellas Pharma US INC | $64.34 | 2019-2023 | Veozah |
| Biohaven Pharmaceuticals, INC. | $62.13 | 2021 | |
| Novo Nordisk INC | $53.77 | 2019-2023 | Rybelsus, Ozempic |
| Sumitomo Pharma America, INC. | $50.34 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $50.09 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $47.76 | 2022-2023 | |
| Abbott Laboratories | $36.02 | 2019 | |
| Abbvie INC. | $34.39 | 2021 | |
| Abiomed | $24.93 | 2022 | |
| Amarin Pharma, INC. | $23.72 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.23 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $22.78 | 2023 | Lagevrio, Belsomra |
| Nestle Healthcare Nutrition INC. | $18.21 | 2021 | |
| Genentech USA, INC. | $17.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.80 | 2022 | |
| Exact Sciences Corporation | $14.88 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $14.33 | 2019 | |
| Bausch Health US, LLC | $14.28 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.43 | 2019 | |
| Sanofi Pasteur INC. | $12.15 | 2019 | |
| Esperion Therapeutics, INC. | $11.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooks Lide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.